Catherine Kim1, Rodica Pop-Busui2, Barbara Braffett3, Patricia A Cleary3, Ionut Bebu3, Hunter Wessells4, Trevor Orchard5, Aruna V Sarma6. 1. Departments of Medicine, Obstetrics and Gynecology, and Epidemiology, University of Michigan, Ann Arbor, MI, USA. 2. Department of Medicine, University of Michigan, Ann Arbor, MI, USA. 3. The Biostatistics Center, George Washington University, Rockville, MD, USA. 4. Department of Urology, University of Washington, Seattle, WA, USA. 5. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 6. Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Abstract
INTRODUCTION: Previous studies have reported that lower testosterone concentrations are associated with cardiovascular autonomic neuropathy (CAN), a risk factor for cardiovascular events. However, no studies have examined this relationship in men with type 1 diabetes, who are at high risk for CAN. AIM: The aim of this study was to examine the associations between testosterone concentrations and measures of CAN in a large, well-characterized cohort of men with type 1 diabetes. METHODS: We conducted an analysis of men in the Diabetes Control and Complications Trial (DCCT), a randomized trial of intensive glucose control, and its observational follow-up the Epidemiology of Diabetes Intervention and Complications (EDIC) Study. Testosterone was measured by liquid chromatography mass spectrometry in stored samples from EDIC follow-up years 10 and 17. Regression models were used to assess the cross-sectional relationships between testosterone and CAN measures. MAIN OUTCOME MEASURES: The main CAN measure from EDIC follow-up year 17 was a standardized composite of R-R variation with paced breathing < 15, or R-R variation 15-20 combined with either a Valsalva ratio ≤ 1.5 or a decrease in diastolic blood pressure > 10 mm Hg upon standing. Continuous R-R variation and Valsalva ratio were secondary outcomes. RESULTS:Lower total and bioavailable testosterone concentrations at follow-up years 10 and 17 were not associated with the presence of CAN at year 17. In analyses using Valsalva ratio as a continuous measure, higher total (P = 0.01) and bioavailable testosterone concentrations (P = 0.005) were associated with a higher (more favorable) Valsalva ratio after adjustment for covariates including age, body mass index, smoking status, hypertension, and glycemia. CONCLUSIONS:Testosterone levels are not associated with CAN among men with type 1 diabetes. Although testosterone is associated with a higher Valsalva ratio, a more favorable indicator, the clinical significance of this association is not known.
RCT Entities:
INTRODUCTION: Previous studies have reported that lower testosterone concentrations are associated with cardiovascular autonomic neuropathy (CAN), a risk factor for cardiovascular events. However, no studies have examined this relationship in men with type 1 diabetes, who are at high risk for CAN. AIM: The aim of this study was to examine the associations between testosterone concentrations and measures of CAN in a large, well-characterized cohort of men with type 1 diabetes. METHODS: We conducted an analysis of men in the Diabetes Control and Complications Trial (DCCT), a randomized trial of intensive glucose control, and its observational follow-up the Epidemiology of Diabetes Intervention and Complications (EDIC) Study. Testosterone was measured by liquid chromatography mass spectrometry in stored samples from EDIC follow-up years 10 and 17. Regression models were used to assess the cross-sectional relationships between testosterone and CAN measures. MAIN OUTCOME MEASURES: The main CAN measure from EDIC follow-up year 17 was a standardized composite of R-R variation with paced breathing < 15, or R-R variation 15-20 combined with either a Valsalva ratio ≤ 1.5 or a decrease in diastolic blood pressure > 10 mm Hg upon standing. Continuous R-R variation and Valsalva ratio were secondary outcomes. RESULTS: Lower total and bioavailable testosterone concentrations at follow-up years 10 and 17 were not associated with the presence of CAN at year 17. In analyses using Valsalva ratio as a continuous measure, higher total (P = 0.01) and bioavailable testosterone concentrations (P = 0.005) were associated with a higher (more favorable) Valsalva ratio after adjustment for covariates including age, body mass index, smoking status, hypertension, and glycemia. CONCLUSIONS:Testosterone levels are not associated with CAN among men with type 1 diabetes. Although testosterone is associated with a higher Valsalva ratio, a more favorable indicator, the clinical significance of this association is not known.
Authors: Evrim B Turkbey; Jye-Yu C Backlund; Saul Genuth; Aditya Jain; Cuilian Miao; Patricia A Cleary; John M Lachin; David M Nathan; Rob J van der Geest; Elsayed Z Soliman; Chia-Ying Liu; João A C Lima; David A Bluemke Journal: Circulation Date: 2011-09-26 Impact factor: 29.690
Authors: Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin Journal: Ann Pharmacother Date: 2014-07-02 Impact factor: 3.154
Authors: Jerzy Krzysztof Wranicz; Marcin Rosiak; Iwona Cygankiewicz; Piotr Kula; Krzysztof Kula; Wojciech Zareba Journal: Ann Noninvasive Electrocardiol Date: 2004-04 Impact factor: 1.468
Authors: Bu B Yeap; Zoë Hyde; Osvaldo P Almeida; Paul E Norman; S A Paul Chubb; Konrad Jamrozik; Leon Flicker; Graeme J Hankey Journal: J Clin Endocrinol Metab Date: 2009-04-07 Impact factor: 5.958
Authors: Timothy J Bradley; Cameron Slorach; Farid H Mahmud; David B Dunger; John Deanfield; Livia Deda; Yesmino Elia; Ronnie L H Har; Wei Hui; Rahim Moineddin; Heather N Reich; James W Scholey; Luc Mertens; Etienne Sochett; David Z I Cherney Journal: Cardiovasc Diabetol Date: 2016-02-16 Impact factor: 9.951